The diagnosis and management of patients with dementing illnesses can be challenging, but the cost of misdiagnosing dementia as Alzheimer's disease can be as high as $14,000 a year, according to a study published in Alzheimer's & Dementia.
The diagnosis and management of patients with dementing illnesses can be challenging, but the cost of misdiagnosing dementia as Alzheimer’s disease (AD) can be high, according to a study published in Alzheimer’s & Dementia.
AD is the most common cause of dementia, accounting for 60% to 80% of all dementias in the US, but it is not uncommon for patients with vascular dementia (VD) or Parkinson’s disease (PD) to be misdiagnosed with AD.
The investigators found that approximately 17% of VD patients were misdiagnosed initially with AD and 8% of PD patients had a history of AD misdiagnosis. And for half of the misdiagnosed patients, a correct diagnosis may not be confirmed for more than 1 year.
“The results of this study suggest substantial levels of AD misdiagnosis among Medicare beneficiaries who eventually receive a corrected diagnosis of either VD or PD,” the authors wrote.
They added that their findings suggest there are potential benefits from early and accurate diagnosis. However, they pointed out that the sensitivity of current clinical diagnostic criteria for AD ranges from 71% to 87% and specificity from as low as 44% to 71%. These numbers suggest substantial misdiagnosis rates among patients with dementia.
Excess medical costs for patients misdiagnosed with AD, who were later confirmed to have VD or PD increases annually for each year of misdiagnosis, peaking at approximately $9500 to $14,000 annually.
The researchers used claims data form the Standard Analytical Files for a 5% random sample of Medicare beneficiaries. They separated patients based on the history of AD diagnosis before confirmed VD/PD diagnosis and considered patients with no AD diagnosis before confirmed VD/PD diagnosis as comparators.
“The significant and potentially avoidable medical resource use and related costs associated with misdiagnosis of AD—and their dissipation after the correction of that diagnosis—suggest substantial value not only of ruling out AD but of doing so as early as possible,” the authors concluded.
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Managed Care Reflections: A Q&A With Charles N. (Chip) Kahn III, MPH
July 30th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The August issue features a conversation with Charles N. (Chip) Kahn III, MPH, the president and CEO of the Federation of American Hospitals and a longtime member of the AJMC editorial board.
Read More
Effects of Adjunctive Cariprazine Formulary Restrictions in Major Depressive Disorder
July 23rd 2025Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved claims.
Read More